– Market expansion outside the US and Europe and start of commercialization of the high volume system, Ikoniscope20max
– First sales of the Ikoniscope20max solution, validating the commercial strategy and the important developments made by the company recently
– Financial results slightly improved compared to H1 2022, with sales of Ikoniscope20max having not yet had a significant impact on revenues: net loss of 0.96 million euros in the first half of 2023 compared to 1.02 million euros in first half of 2022
Paris, October 30, 2023 – 7:30 a.m. CET – Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and precise detection of cancers using a unique, fully automated solution for medical analysis laboratories, announces today its financial results for the first half ending June 30, 2023, approved by the Board of Directors on October 29, 2023, and provides an update on its activity as well as its development strategy.